Reduction of Transfusion Burden (TB), Hemoglobin Increase, and Dose Titration in the COMMANDS Study of Luspatercept Versus Epoetin Alfa (EA) in Erythropoietin-Stimulating Agent (ESA)-Naive Patients With Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0
|
作者：
Komrokji, Rami S. [1 ]
Platzbecker, Uwe [2 ]
Della Porta, Matteo [3 ,4 ]
Santini, Valeria [5 ]
Garcia-Manero, Guillermo [6 ]
Li, Jiahui [7 ]
Zhang, Jennie [7 ]
Giuseppi, Ana Carolina [7 ]
Kreitz, Sandra [8 ]
Pozharskaya, Veronika [7 ]
Keeperman, Karen L. [7 ]
Rose, Shelonitda [7 ]
Hughes, Christina [7 ]
Valcarcel, David [9 ]
Fenaux, Pierre [10 ]
Shortt, Jake [11 ,12 ]
机构：
[1] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[2] Dept Hematol Cell Hematol & Hemostaseol, Leipzig, Germany
[3] Canc Ctr IRCCS Humanitas Res Hosp, Milan, Italy
[4] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[5] Univ Florence, AOUC, MDS Unit, Hematol, Florence, Italy
[6] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Bristol Myers Squibb Co, Celgene Int Sarl, Boudry, Switzerland
[9] Hosp Univ Vall Hebron, Barcelona, Spain
[10] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
[11] Monash Univ, Melbourne, Vic, Australia
[12] Monash Hlth, Melbourne, Vic, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
MDS; myelodysplastic neoplasms; erythroid response; clinical benefit; RBC transfusion independence; ESA-naive; phase III;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MDS-234
引用
收藏
页码：S358 / S359
页数：2
相关论文
共 31 条
  • [21] Rigosertib Oral in Transfusion Dependent Lower Risk Myelodysplastic Syndromes (LR-MDS): Optimization of Dose and Rate of Transfusion Independence (TI) or Transfusion Reduction (TR) in a Single-Arm Phase 2 Study
    Raza, Azra
    Al-Kali, Aref
    Tibes, Raoul
    Spitzer, Gary
    Gaddh, Manila
    Tycko, Benjamin
    Lee, Sangmin
    Galili, Naomi
    Ali, Abdullah Mahmood
    Mears, John G.
    Mukherjee, Siddhartha
    Shelton, Ryan
    Fruchtman, Steven M.
    Petrone, Michael E.
    Zbyszewski, Patrick S.
    Heaney, Mark Lawrence
    BLOOD, 2017, 130
  • [22] LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS): LONG-TERM RESULTS FROM PHASE 2 PACE-MDS STUDY
    Giagounidis, A.
    Germing, U.
    Goetze, K.
    Kiewe, P.
    Wolff, T.
    Mayer, K.
    Chromik, J.
    Radsak, M.
    Wilson, D.
    Zhang, X.
    Laadem, A.
    Sherman, M. L.
    Attie, K. M.
    Linde, P. G.
    Platzbecker, U.
    HAEMATOLOGICA, 2017, 102 : 264 - 264
  • [23] Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
    Uwe Platzbecker
    Valeria Santini
    Rami S. Komrokji
    Amer M. Zeidan
    Guillermo Garcia-Manero
    Rena Buckstein
    Dimana Miteva
    Karen Keeperman
    Natalia Holot
    Jose Alberto Nadal
    Yinzhi Lai
    Sadanand Vodala
    Barbara Rosettani
    Ana Carolina Giuseppi
    Aylin Yucel
    Pierre Fenaux
    Leukemia, 2023, 37 : 2314 - 2318
  • [24] Multiple periods of transfusion independence (TI) with luspatercept (LUSP) treatment (Tx) and the impact of dose escalation in patients (Pts) with lower-risk myelodysplastic syndromes (LR-MDS) with ring sideroblasts (RS) from the MEDALIST study
    Platzbecker, U.
    Santini, V
    Komrokji, R. S.
    Zeidan, A. M.
    Garcia-Manero, G.
    Buckstein, R. J.
    Oliva, E. N.
    Pozharskaya, V
    Nadal, J. A.
    Miteva, D.
    Fenaux, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 18 - 19
  • [25] Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts
    Platzbecker, Uwe
    Santini, Valeria
    Komrokji, Rami S.
    Zeidan, Amer M.
    Garcia-Manero, Guillermo
    Buckstein, Rena
    Miteva, Dimana
    Keeperman, Karen
    Holot, Natalia
    Nadal, Jose Alberto
    Lai, Yinzhi
    Vodala, Sadanand
    Rosettani, Barbara
    Giuseppi, Ana Carolina
    Yucel, Aylin
    Fenaux, Pierre
    LEUKEMIA, 2023, 37 (11) : 2314 - 2318
  • [26] Benefit of Continuing Luspatercept Therapy in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Did Not Achieve Red Blood Cell Transfusion Independence (RBC-TI) by Week 25 in the MEDALIST Study
    Platzbecker, Uwe
    Germing, Ulrich
    Fenaux, Pierre
    Buckstein, Rena
    Santini, Valeria
    Diez-Campelo, Maria
    Tang, Derek
    Ito, Rodrigo
    Fabre, Shannon
    Mantovani, Emily
    Zhang, George
    Ha, Xianwei
    Miteva, Dimana
    Hughes, Christina
    Khan, Wasiulla
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 142 - 143
  • [27] CHANGES IN TRANSFUSION BURDEN (TB), HEMOGLOBIN (HB), SERUM FERRITIN (SF), AND IRON CHELATION THERAPY (ICT) USE IN PATIENTS WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES WITH RING SIDEROBLASTS TREATED WITH LUSPATERCEPT FROM THE MEDALIST STUDY
    Platzbecker, U.
    Garcia-Manero, G.
    Komrokji, R. S.
    Tang, D.
    Ito, R.
    Fabre, S.
    Zhang, G.
    Ha, X.
    Mantovani, E.
    Miteva, D.
    Zinger, T.
    Fenaux, P.
    VALUE IN HEALTH, 2021, 24 : S19 - S19
  • [28] IMerge: Results from a phase 3, randomized, double-blind, placebo-controlled study of imetelstat in patients (pts) with heavily transfusion dependent (TD) non-del(5q) lower-risk myelodysplastic syndromes (LR-MDS) relapsed/refractory (R/R) to erythropoiesis stimulating agents (ESA).
    Zeidan, Amer Methqal
    Platzbecker, Uwe
    Santini, Valeria
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Savona, Michael R.
    Madanat, Yazan F.
    Diez-Campelo, Maria
    Valcarcel, David
    Illmer, Thomas
    Jonasova, Anna
    Belohlavkova, Petra
    Sherman, Laurie Jill
    Berry, Tymara
    Dougherty, Souria
    Shah, Sheetal
    Sun, Libo
    Wan, Ying
    Huang, Fei
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Almeida, A.
    Giagounidis, A.
    Groepper, S.
    Jonasova, A.
    Vey, N.
    Mufti, G. J.
    Buckstein, R.
    Mittelman, M.
    Platzbecker, U.
    Shpilberg, O.
    Ram, R.
    del Canizo, C.
    Gattermann, N.
    Ozawa, K.
    Risueno, A.
    MacBeth, K. J.
    Zhong, J.
    Seguy, F.
    Hoenekopp, A.
    Beach, C. L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S60 - S61
  • [30] Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents
    Santini, Valeria
    Almeida, Antonio
    Giagounidis, Aristoteles
    Groepper, Stefanie
    Jonasova, Anna
    Vey, Norbert
    Mufti, Ghulam J.
    Buckstein, Rena
    Mittelman, Moshe
    Platzbecker, Uwe
    Shpilberg, Ofer
    Ram, Ron
    del Canizo, Consuelo
    Gattermann, Norbert
    Ozawa, Keiya
    Risueno, Alberto
    MacBeth, Kyle J.
    Zhong, Jianhua
    Seguy, Francis
    Hoenekopp, Albert
    Beach, C. L.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (25) : 2988 - +
1234